## LRCX: Lam Research Corporation - XLK: Technology

### Executive Summary

No thesis match: MRS_20 0.9% below STRENGTH zone (4.0-10.0%); PEG 2.39 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($144.85)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Lam Research (LRCX) Stock Is Up, What You Need To Know**
- Source: Finviz | 20251202T111100 | Somewhat-Bullish | Relevance: 99%
- Shares of Lam Research (NASDAQ:LRCX) jumped 2.9% after Morgan Stanley raised its price target to $158 from $137, maintaining an "Equalweight" rating. This optimistic outlook on the semiconductor equipment maker's valuation comes amidst renewed investor interest and strong financial performance. The stock's performance reflects its volatility and the market's positive, yet cautious, reception to significant news, like the broader tech sector uplift driven by AI developments and potential interest rate cuts.

**2. Lam Research Corporation $LRCX Shares Purchased by VestGen Advisors LLC**
- Source: MarketBeat | 20251201T131849 | Bullish | Relevance: 99%
- VestGen Advisors LLC significantly increased its stake in Lam Research Corporation (NASDAQ:LRCX) by 279.8% in Q2, bringing their total holdings to 18,332 shares valued at approximately $1.78 million. Other institutional investors also adjusted their positions, with Mackenzie Financial Corp increasing its stake to over 1.74 million shares. Lam Research exceeded Q2 earnings estimates and received a consensus "Moderate Buy" rating from analysts, with various firms setting price targets above its current trading price.

**3. Lam Research (LRCX) Jumps on Morgan Stanley Upgrade: Is the AI Wafer-Equipment Rally Running Hot or Just Getting Started?**
- Source: ts2.tech | 20251202T204254 | Somewhat-Bullish | Relevance: 99%
- Lam Research (LRCX) stock climbed after Morgan Stanley raised its price target, amidst a year of significant gains driven by AI wafer demand. The article examines whether this rally is sustainable, considering analyst ratings, options activity, strong Q1 2026 financials, and the impact of China exposure and regulatory risks. Despite high valuations, Lam Research is well-positioned for future growth in the semiconductor industry with strategic investments and capital returns.

**4. Lam Research Corporation $LRCX Shares Acquired by MBM Wealth Consultants LLC**
- Source: MarketBeat | 20251201T125831 | Bullish | Relevance: 99%
- MBM Wealth Consultants LLC significantly increased its stake in Lam Research Corporation (NASDAQ:LRCX) by 25.9% in Q2, acquiring an additional 4,088 shares and now owning 19,877 shares valued at $1.935 million. Despite this institutional buying, company insiders have been net sellers, with significant sales by Director Bethany Mayer and SVP Vahid Vahedi totaling $14.9 million in the last three months. Lam Research recently beat quarterly earnings estimates and provided optimistic Q2 FY2026 guidance, alongside declaring a quarterly dividend of $0.26 per share.

**5. Scotia Capital Inc. Sells 9,284 Shares of Lam Research Corporation $LRCX**
- Source: MarketBeat | 20251202T122309 | Neutral | Relevance: 98%
- Scotia Capital Inc. reduced its stake in Lam Research Corporation ($LRCX) by 45% in the second quarter, selling 9,284 shares and retaining 11,362 shares valued at $1.11 million. This comes as Lam Research reported strong earnings, beating revenue and EPS estimates, and provided positive Q2 2026 guidance. Insider selling has been significant, with 102,608 shares offloaded in the past three months, reducing insider ownership to 0.31%.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $158 | $137 | +15% |
| 2025-11-25 | UBS | $175 | $165 | +6% |
| 2025-11-12 | Citigroup | $190 | $175 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Equal-Weight |
| 2025-11-25 | UBS | main | Buy |
| 2025-11-12 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 11 ($0.00M) |
| Sells | 6 ($14.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.4% (+0.3%)
- Blackrock Inc.: 9.9% (+1.7%)
- JPMORGAN CHASE & CO: 4.8% (+47.4%)
- State Street Corpora: 4.8% (+0.4%)
- Geode Capital Manage: 2.7% (-0.5%)

### Key Risks

1. Heavy insider selling: $14M sold (6 transactions in 90 days).
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +10%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +2.4% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.39 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 62%, ROA 20%, margin 30%). Balance sheet: strong liquidity (2.2x), $1.6B free cash flow. Analyst sentiment positive (3 raises, avg +10%). Insider selling cluster ($14.1M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $212.2B |
| Beta | 1.78 |
| 52W Range | $56.32 - $169.69 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.39 |
| Forward P/E | 28.3 |
| Current P/E | 32.8 |
| YoY Growth | 15.8% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from -1.4% to 0.9% (+2.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.1pp (needs >4.0% for momentum thesis). MRS_5 at 1.2% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 57.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.91% (CS: 69) | Neutral |
| RSI_14 | 56.9 | Neutral |
| MACD Histogram | 0.06 | Bullish |
| vs SMA20 | 1.028x | Above |
| vs SMA50 | 1.071x | Above |
| vs SMA200 | 1.532x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $158.19
- **Stop Loss:** $144.85 (8.4% risk)
- **Target:** $171.53 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 89
- **Position Value:** $14,078.91
- **Portfolio %:** 14.08%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-01-28 (Est: $1.16)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.22 | $1.26 | +3.3% |
| 2025Q2 | $1.21 | $1.33 | +10.4% |
| 2025Q1 | $1.00 | $1.04 | +4.1% |
| 2024Q4 | $0.88 | $0.91 | +3.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*